RISalud-ANDALUCÍA
Not a member yet
18682 research outputs found
Sort by
Efficacy and Safety of Celiac Plexus Neurolysis in the Treatment of Chronic Pain Secondary to Oncological Pathology of the Upper Hemiabdomen: A Systematic Review and Meta-Analysis
No full textYe
Vol. 28, nº 30. Abordaje de las infecciones de transmisión sexual con la visión de un distrito rural y un hospital comarcal
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 29/2023 y acumulado desde la semana 01/2023. Datos provisionales. Incluye además el artículo titulado “Abordaje de las infecciones de transmisión sexual con la visión de un distrito rural y un hospital comarcal”, de “María Amparo Gómez Vidal, José Raúl Dueñas Fuentes”.Ye
Vol. 28, nº 7. TABLA EDO año 2022 por provincias. Datos provisionales a fecha 6 de febrero de 2023
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 06/2023 y acumulado desde semana 1/2023. Datos provisionales. Incluye además el artículo titulado "TABLA EDO año 2022 por provincias Datos provisionales a fecha 6 de febrero de 2023", de "SVSL. SVEA".Ye
Vol. 28, nº 33. La mortalidad y sus causas en Andalucía en 2021
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 32/2023 y acumulado desde la semana 01/2023. Datos provisionales. Incluye además el artículo titulado “La mortalidad y sus causas en Andalucía en 2021”, de “Soledad Márquez Calderón”.Ye
Is zoledronate a safe and effective treatment option in chronic nonbacterial osteomyelitis?
No full textPrograma de cribado neonatal de enfermedades endocrino-metabólicas de Andalucía: instrucciones para profesionales 2023
No full textEl Programa de Cribado Neonatal de Enfermedades Endocrino-Metabólicas de Andalucía tiene como objetivo la detección precoz de un grupo de enfermedades en las que existe una intervención eficaz que permite modificar favorablemente su pronóstico, reduciendo la morbimortalidad y las posibles discapacidades asociadas a ellas.Ye
Vol. 28, nº 28. Apoyo de la epidemiología al seguimiento de los objetivos asistenciales del contrato programa en el distrito sanitario Almería.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 27/2023 y acumulado desde la semana 01/2023. Datos provisionales. Incluye además el artículo titulado “Apoyo de la epidemiología al seguimiento de los objetivos asistenciales del contrato programa en el distrito sanitario Almería”, de “Pilar Barroso García, Juan González Pérez”.Ye
Biblioteca Virtual Del Sistema Sanitario Público De Andalucía (BV-SSPA): Recursos y servicios
No full textYe
Off-label prescription of BNT162b2 mRNA COVID-19 vaccine to <5-year-old children in the European Union.
No full textOff-label or unlicensed use of medicinal products are those that are prescribed outside the terms of their authorisation by the regulatory agency in a given jurisdiction i e unapproved indication age group posology route or schedule of administration As the highly transmissible Omicron variant of SARS-CoV-2 becomes prevalent in the US the EU and elsewhere Pfizer BioNTech announced that the results of the ongoing phase 2 3 trial NCT04816643 assessing its BNT162b2 mRNA vaccine in 0 5 4-year-old children will be delayed to test a 3- dose regimen A debate has emerged in the USA on whether this vaccine could be ethically prescribed to this age group of children Whilst some commentators considered its prescription to be ethically acceptable in vulnerable kids at high risk of developing severe COVID-19 1 2 recommendation against off-label paediatric use has been issued by the US Food and Drug Administration American Academy of Paediatrics and Centers for Disease Control and Prevention In addition this latter has warned that off-label vaccine 5-year-old recipients may not be eligible for federal compensation in case of adverse events 1S
A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
No full textNo multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported. Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016-2021. DILI cases or non-DILI acute liver injury controls following causality assessment were enrolled. Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis (n = 42) and viral hepatitis (n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre-existing liver disease. DILI cases and non-DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin-clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug-induced autoimmune-like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver-related death), and another six received liver transplantation. In this first multi-national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI.S